Researchers report that biosimilar use was not influenced by disease type but correlated with treatment sequence, shorter ...

The FDA has approved Celltrion's Eydenzelt, a new aflibercept biosimilar, enhancing treatment options for retinal diseases in the US.

A recent study confirms the stability of XSB-001 biosimilar for retinal diseases under realistic clinical handling conditions ...

A review of the safety of biosimilar DMARDs during pregnancy reveals critical evidence gaps and the need for informed clinical guidance.

The latest advancements in global biosimilar access include new treatments, strategic partnerships, and competitive market ...

AVT06, a promising biosimilar to aflibercept (Eylea), shows comparable efficacy and safety for treating neovascular age-related macular degeneration (AMD), enhancing patient access. AVT06, a proposed ...

Omalizumab biosimilars promise significant savings for European health systems, enhancing access to vital therapies for patients with severe allergies. Biosimilars have been touted for years as a way ...

Number 5: The FDA has approved Bosaya (denosumab-kyqq) and Aukelso (denosumab-kyqq), the sixth pair of denosumab biosimilars to receive the green light from the agency. The approvals, granted to ...

Major advancements in biosimilars emerge in Europe and Middle East and North Africa (MENA) region, enhancing patient access and affordability in critical therapeutic areas. In 2025, European, Asian, ...